In EDS ansehen

Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway

Gespeichert in:
Bibliographische Detailangaben
Titel: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway
Autoren: Nathalie C. Støer, Siri Vangen, Deependra Singh, Renée T. Fortner, Solveig Hofvind, Giske Ursin, Edoardo Botteri
Quelle: Br J Cancer
Verlagsinformationen: Springer Science and Business Media LLC, 2024.
Publikationsjahr: 2024
Schlagwörter: Norway, Hormone Replacement Therapy, Estrogen Replacement Therapy, Breast Neoplasms, Estrogens, Middle Aged, Article, Body Mass Index, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, 631/67/1347, Female [MeSH], Estrogen Replacement Therapy/statistics, Breast Neoplasms/chemically induced [MeSH], Aged [MeSH], Hormone Replacement Therapy/adverse effects [MeSH], Humans [MeSH], Estrogens/adverse effects [MeSH], Middle Aged [MeSH], Risk Factors [MeSH], Breast Neoplasms/epidemiology [MeSH], Estrogen Replacement Therapy/adverse effects [MeSH], Estrogens/administration, Cohort Studies [MeSH], Norway/epidemiology [MeSH], Body Mass Index [MeSH], Menopause [MeSH], 692/499, Progestins/administration, Progestins/adverse effects [MeSH], article, Risk Factors, Humans, Female, Menopause, Progestins, Aged
Beschreibung: Background It is important to monitor the association between menopausal hormone therapy (HT) use and breast cancer (BC) risk with contemporary estimates, and specifically focus on HT types and new drugs. Methods We estimated hazard ratios (HR) of BC risk according to HT type, administration route and individual drugs, overall and stratified by body mass index (BMI), molecular subtype and detection mode, with non-HT use as reference. Results We included 1,275,783 women, 45+ years, followed from 2004, for a median of 12.7 years. Oral oestrogen combined with daily progestin was associated with the highest risk of BC (HR 2.42, 95% confidence interval (CI) 2.31–2.54), with drug-specific HRs ranging from Cliovelle®: 1.63 (95% CI 1.35–1.96) to Kliogest®: 2.67 (2.37–3.00). Vaginal oestradiol was not associated with BC risk. HT use was more strongly associated with luminal A cancer (HR 1.97, 95% CI 1.86–2.09) than other molecular subtypes, and more strongly with interval (HR 2.00, 95% CI: 1.85–2.15) than screen-detected (HR 1.40, 95% CI 1.34–1.47) BC in women 50–71 years. HRs for HT use decreased with increasing BMI. Conclusions The use of oral and transdermal HT was associated with an increased risk of BC. The associations varied according to HT type, individual drugs, molecular subtype, detection mode and BMI.
Publikationsart: Article
Other literature type
Sprache: English
ISSN: 1532-1827
0007-0920
DOI: 10.1038/s41416-024-02590-1
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38740969
https://repository.publisso.de/resource/frl:6509073
https://hdl.handle.net/10037/35072
Rights: CC BY
URL: http://creativecommons.org/licenses/by/3.0/igo/Open Access The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the World Health Organization, its representatives, or the countries they represent. This article is licensed under the terms of the Creative Commons Attribution 3.0 IGO License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the World Health Organization, provide a link to the Creative Commons licence and indicate if changes were made. The use of the World Health Organization’s name, except in reference to the article, and the use of the World Health Organization’s logo, is not authorized as part of this licence. The link provided below includes additional terms and conditions of the licence. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/3.0/igo/ (http://creativecommons.org/licenses/by/3.0/igo/) .
Dokumentencode: edsair.doi.dedup.....b5ddf0a8c965783f1dc7b2f80e0a10dc
Datenbank: OpenAIRE
Beschreibung
Abstract:Background It is important to monitor the association between menopausal hormone therapy (HT) use and breast cancer (BC) risk with contemporary estimates, and specifically focus on HT types and new drugs. Methods We estimated hazard ratios (HR) of BC risk according to HT type, administration route and individual drugs, overall and stratified by body mass index (BMI), molecular subtype and detection mode, with non-HT use as reference. Results We included 1,275,783 women, 45+ years, followed from 2004, for a median of 12.7 years. Oral oestrogen combined with daily progestin was associated with the highest risk of BC (HR 2.42, 95% confidence interval (CI) 2.31–2.54), with drug-specific HRs ranging from Cliovelle®: 1.63 (95% CI 1.35–1.96) to Kliogest®: 2.67 (2.37–3.00). Vaginal oestradiol was not associated with BC risk. HT use was more strongly associated with luminal A cancer (HR 1.97, 95% CI 1.86–2.09) than other molecular subtypes, and more strongly with interval (HR 2.00, 95% CI: 1.85–2.15) than screen-detected (HR 1.40, 95% CI 1.34–1.47) BC in women 50–71 years. HRs for HT use decreased with increasing BMI. Conclusions The use of oral and transdermal HT was associated with an increased risk of BC. The associations varied according to HT type, individual drugs, molecular subtype, detection mode and BMI.
ISSN:15321827
00070920
DOI:10.1038/s41416-024-02590-1